Afficher la notice abrégée

Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database

dc.rights.licenseopenen_US
dc.contributor.authorANNONAY, Mylene
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorGAUQUELIN, Lisa
dc.contributor.authorGEISS, Romain
dc.contributor.authorUNG, Mony
dc.contributor.authorCRISTOL-DALSTEIN, Laurence
dc.contributor.authorMOURET-REYNIER, Marie Ange
dc.contributor.authorGONCALVES, Anthony
dc.contributor.authorABADIE-LACOURTOISIE, Sophie
dc.contributor.authorFRANCOIS, Eric
dc.contributor.authorPERRIN, Christophe
dc.contributor.authorLE FEL, Johan
dc.contributor.authorLORGIS, Veronique
dc.contributor.authorSERVENT, Veronique
dc.contributor.authorUWER, Lionel
dc.contributor.authorJOUANNAUD, Christelle
dc.contributor.authorLEHEURTEUR, Marianne
dc.contributor.authorJOLY, Florence
dc.contributor.authorCAMPION, Loic
dc.contributor.authorCOURTINARD, Coralie
dc.contributor.authorVILLACROUX, Olivier
dc.contributor.authorPETIT, Thierry
dc.contributor.authorSOUBEYRAN, Pierre
dc.contributor.authorTERRET, Catherine
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBELLERA, Carine
dc.contributor.authorBRAIN, Etienne
dc.contributor.authorDELALOGE, Suzette
dc.date.accessioned2021-12-07T09:43:51Z
dc.date.available2021-12-07T09:43:51Z
dc.date.issued2021-10-01
dc.identifier.issn1532-3080 (Electronic) 0960-9776 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/124018
dc.description.abstractEnBACKGROUND: Treatment and outcomes of patients with HER2-positive (HER2+) metastatic breast cancer (MBC) have dramatically improved over the past 20 years. This work evaluated treatment patterns and outcomes according to age. METHODS: Women who initiated a treatment for HER2+ MBC between 2008 and 2016 in one of the 18 French comprehensive centers part of the ESME program were included. Objectives were the description of first-line treatment patterns, overall survival (OS), first-line progression-free survival (PFS), and prognostic factors among patients aged 70 years or more (70+), or less than 70 (<70). RESULTS: Of 4045 women diagnosed with an HER2+ MBC, 814 (20%) were 70+. Standard first-line treatment (chemotherapy combined with an anti-HER2 therapy) was prescribed in 65% of 70+ versus 89% of <70 patients (p < 0.01). Median OS was 49.2 (95% CI, 47.1-52.4), 35.3 (95% CI, 31.5-37.0) and 54.2 months (95% CI, 50.8-55.7) in the whole population, in patients 70+ and <70, respectively. Corresponding median PFS1 were 12.8 (95% CI, 12.3-13.3), 11.1 (95% CI, 10.0-12.3) and 13.2 months (95% CI, 12.7-13.9), respectively. In 70+ women, initiation of non-standard first-line treatment had an independent detrimental time-varying effect on both OS and PFS (HR on OS at 1 year: chemotherapy without anti-HER2 2.79 [95% CI: 2.05-3.79]; endocrine therapy and/or anti-HER2 1.96 [95% CI: 1.43-2.69]). CONCLUSIONS: In this large retrospective real-life database, older women with HER2+ MBC received standard first-line treatment less frequently than younger ones. This was independently associated with a worse outcome, but confounding factors and usual selection biases cannot be ruled out.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enMetastatic breast cancer
dc.subject.enOverall survival
dc.subject.enElderly
dc.subject.enHER2
dc.title.enTreatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.breast.2021.09.011en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34624756en_US
bordeaux.journalBreasten_US
bordeaux.page138-146en_US
bordeaux.volume60en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamEPICENE_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03468488
hal.version1
hal.date.transferred2021-12-07T09:43:56Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Breast&amp;rft.date=2021-10-01&amp;rft.volume=60&amp;rft.spage=138-146&amp;rft.epage=138-146&amp;rft.eissn=1532-3080%20(Electronic)%200960-9776%20(Linking)&amp;rft.issn=1532-3080%20(Electronic)%200960-9776%20(Linking)&amp;rft.au=ANNONAY,%20Mylene&amp;GAUQUELIN,%20Lisa&amp;GEISS,%20Romain&amp;UNG,%20Mony&amp;CRISTOL-DALSTEIN,%20Laurence&amp;rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_TB_2021_Annonay.pdf
Taille:
940.4Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
811octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée